Invasive fungal infections: evolving challenges for diagnosis and therapeutics (Q34636544)

3 August 2017

1 reference

title

Invasive fungal infections: evolving challenges for diagnosis and therapeutics (English)

1 reference

invasive fungal infections

3 August 2017

main subject

1 reference

Michael Ellis

1

1 reference

3 August 2017

language of work or name

1 reference

1 May 2002

1 reference

3 August 2017

1 reference

3 August 2017

volume

38

1 reference

3 August 2017

issue

12-13

1 reference

3 August 2017

page(s)

947-957

1 reference

The epidemiology of hematogenous candidiasis caused by different Candida species

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S0161-5890(02)50022-6

7 January 2021

Dose-dependent antifungal activity and nephrotoxicity of amphotericin B colloidal dispersion in experimental pulmonary aspergillosis

1 reference

https://api.crossref.org/works/10.1016/S0161-5890(02)50022-6

7 January 2021

Lipid-based antifungal agents: current status

1 reference

https://api.crossref.org/works/10.1016/S0161-5890(02)50022-6

7 January 2021

Reliability of clinical research on invasive fungal infections: a systematic review of the literature

1 reference

https://api.crossref.org/works/10.1016/S0161-5890(02)50022-6

7 January 2021

Mortality and costs of acute renal failure associated with amphotericin B therapy

1 reference

https://api.crossref.org/works/10.1016/S0161-5890(02)50022-6

7 January 2021

Comparison of Serum Galactomannan Antigen Detection and Competitive Polymerase Chain Reaction for Diagnosing Invasive Aspergillosis

1 reference

https://api.crossref.org/works/10.1016/S0161-5890(02)50022-6

7 January 2021

Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery

1 reference

https://api.crossref.org/works/10.1016/S0161-5890(02)50022-6

7 January 2021

Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia

1 reference

https://api.crossref.org/works/10.1016/S0161-5890(02)50022-6

7 January 2021

Efficacy of low-dose dopamine in preventing amphotericin B nephrotoxicity in bone marrow transplant patients and leukemia patients

1 reference

https://api.crossref.org/works/10.1016/S0161-5890(02)50022-6

7 January 2021

Th1 and Th2 cytokines in mice with invasive aspergillosis.

1 reference

https://api.crossref.org/works/10.1016/S0161-5890(02)50022-6

7 January 2021

A New Classification and Diagnostic Criteria for Invasive Fungal Sinusitis

1 reference

https://api.crossref.org/works/10.1016/S0161-5890(02)50022-6

7 January 2021

Amphotericin B preparations: a maximum tolerated dose in severe invasive fungal infections?

1 reference

https://api.crossref.org/works/10.1016/S0161-5890(02)50022-6

7 January 2021

Double-blind randomized study of the effect of infusion rates on toxicity of amphotericin B

1 reference

https://api.crossref.org/works/10.1016/S0161-5890(02)50022-6

7 January 2021

The effect of fluconazole as prophylaxis for neutropenic patients on the isolation of Candida spp. from surveillance cultures

1 reference

https://api.crossref.org/works/10.1016/S0161-5890(02)50022-6

7 January 2021

Open Lung Biopsy Provides a Higher and More Specific Diagnostic Yield Compared to Broncho-Alveolar Lavage in Immunocompromised Patients

1 reference

https://api.crossref.org/works/10.1016/S0161-5890(02)50022-6

7 January 2021

An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis.

1 reference

https://api.crossref.org/works/10.1016/S0161-5890(02)50022-6

7 January 2021

Fungal endocarditis: evidence in the world literature, 1965-1995.

1 reference

https://api.crossref.org/works/10.1016/S0161-5890(02)50022-6

7 January 2021

Massive intracerebral aspergillosis responding to combination high dose liposomal amphotericin B and cytokine therapy without surgery

1 reference

https://api.crossref.org/works/10.1016/S0161-5890(02)50022-6

7 January 2021

Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016/S0161-5890(02)50022-6

7 January 2021

Discriminant scorecard for diagnosis of invasive pulmonary aspergillosis in patients with acute leukemia

1 reference

https://api.crossref.org/works/10.1016/S0161-5890(02)50022-6

7 January 2021

Potential role of phospholipases in virulence and fungal pathogenesis

1 reference

https://api.crossref.org/works/10.1016/S0161-5890(02)50022-6

7 January 2021

Trends in the postmortem epidemiology of invasive fungal infections at a university hospital

1 reference

https://api.crossref.org/works/10.1016/S0161-5890(02)50022-6

7 January 2021

Candida ciferrii, a new fluconazole-resistant yeast causing systemic mycosis in immunocompromised patients

1 reference

https://api.crossref.org/works/10.1016/S0161-5890(02)50022-6

7 January 2021

New systematically active antimycotics from the beta-blocker category

1 reference

https://api.crossref.org/works/10.1016/S0161-5890(02)50022-6

7 January 2021

Epidemiology of nosocomial fungal infections, with emphasis on Candida species

1 reference

https://api.crossref.org/works/10.1016/S0161-5890(02)50022-6

7 January 2021

An approach to intensive antileukemia therapy in patients with previous invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1016/S0161-5890(02)50022-6

7 January 2021

Crescent sign in invasive pulmonary aspergillosis: frequency and related CT and clinical factors

1 reference

https://api.crossref.org/works/10.1016/S0161-5890(02)50022-6

7 January 2021

Liposomal amphotericin B (AmBisome) reduces dissemination of infection as compared with amphotericin B deoxycholate (Fungizone) in a rate model of pulmonary aspergillosis.

1 reference

https://api.crossref.org/works/10.1016/S0161-5890(02)50022-6

7 January 2021

Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections

1 reference

https://api.crossref.org/works/10.1016/S0161-5890(02)50022-6

7 January 2021

Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation

1 reference

https://api.crossref.org/works/10.1016/S0161-5890(02)50022-6

7 January 2021

National Surveillance of Nosocomial Blood Stream Infection Due to Candida albicans: Frequency of Occurrence and Antifungal Susceptibility in the SCOPE Program

1 reference

https://api.crossref.org/works/10.1016/S0161-5890(02)50022-6

7 January 2021

A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016/S0161-5890(02)50022-6

7 January 2021

A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients

1 reference

https://api.crossref.org/works/10.1016/S0161-5890(02)50022-6

7 January 2021

Need for Alternative Trial Designs and Evaluation Strategies for Therapeutic Studies of Invasive Mycoses

1 reference

https://api.crossref.org/works/10.1016/S0161-5890(02)50022-6

7 January 2021

Treatment of Acute Myeloid Leukemia with Cytokines: Effect on Duration of Neutropenia and Response to Infections

1 reference

https://api.crossref.org/works/10.1016/S0161-5890(02)50022-6

7 January 2021

Molecular probes for diagnosis of fungal infections

1 reference

https://api.crossref.org/works/10.1016/S0161-5890(02)50022-6

7 January 2021

Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC)

1 reference

https://api.crossref.org/works/10.1016/S0161-5890(02)50022-6

7 January 2021

Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group

1 reference

https://api.crossref.org/works/10.1016/S0161-5890(02)50022-6

7 January 2021

Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016/S0161-5890(02)50022-6

7 January 2021

A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016/S0161-5890(02)50022-6

7 January 2021

Surgical management of invasive pulmonary aspergillosis in immunocompromised patients

1 reference

https://api.crossref.org/works/10.1016/S0161-5890(02)50022-6

7 January 2021

10.1016/S0161-5890(02)00022-6

Identifiers

DOI

1 reference

3 August 2017

1 reference